XReality Group

Additional Working Capital Secured

xReality Group Limited (“XRG” or the “Company”) is pleased to announce that it has secured an additional $500,000 in working capital through its senior debt holder, Causeway Financial. The additional working capital will be utilised to provide inventory for the increasing demand in the United States markets.


Key Highlights:

  • XRG senior debt facility with Causeway Financial has been increased by $500,000 and the term has been extended to September 2025. All other terms and conditions of the loan facility remain unchanged, ensuring the company retains its favourable borrowing conditions.
  • The additional funds will be used to manage the required inventory to address the significant increase in Operator XR orders. Maintaining a larger inventory of hardware in the US will expedite the delivery times and streamline the logistics involved.

XRG CEO, Wayne Jones said: “The additional working capital gives the company increased financial flexibility to streamline our processes for delivery and capitalise on the current traction we are experiencing in the US Law Enforcement markets.”

This ASX Release is authorised by the Board of xReality Group Limited.


Click here for the full ASX Release

This article includes content from xReality Group, licensed for the purpose of publishing on Investing News Australia. This article does not constitute financial product advice. It is your responsibility to perform proper due diligence before acting upon any information provided here. Please refer to our full disclaimer here.

XRG:AU
XReality Group

XReality Group Investor Kit

  • Corporate info
  • Insights
  • Growth strategies
  • Upcoming projects

GET YOUR FREE INVESTOR KIT

The Conversation (0)
XReality Group (ASX:XRG)

XReality Group


Keep reading...Show less
Linius Technologies Limited

Linius Technologies Limited (ASX: LNU) – Trading Halt

Description

The securities of Linius Technologies Limited (‘LNU’) will be placed in trading halt at the request of LNU, pending it releasing an announcement. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of the commencement of normal trading on Monday, 8 July 2024 or when the announcement is released to the market.

Keep reading...Show less
XReality Group

Operator XR – Sales Update June 24

xReality Group Limited (“XRG” or the “Company”) is pleased to provide the following sales update for Operator XR, a wholly owned subsidiary of xReality Group Ltd. Operator XR provides Military and Law Enforcement agencies around the world with a unique, integrated Mission Planning & Rehearsal System, which is portable, secure, and highly immersive.

Keep reading...Show less
XReality Group

Operator XR –Awarded $800,000 Government Contract

xReality Group Limited (“XRG” or the “Company”) is pleased to announce the sale of multiple systems of its Operator XR Virtual Reality Training System to a new Australian State Government customer.
Keep reading...Show less
Linius Technologies Limited

Linius Now Live with First Deployment in American Football

Linius Technologies Limited (ASX:LNU) (Linius or Company) – the only cloud-based solution that unlocks the value of video archives with immersive, deeply personalized viewer experiences via its Linius Media Solutions portfolio – is pleased to announce that the deployment of its sports solution, Whizzard, is now live with its customer Lone Star Conference.

Keep reading...Show less
Sona's Cancer Therapy Triggers Abscopal Effect, Eliminating Distant Tumors In Preclinical Melanoma Study

Sona's Cancer Therapy Triggers Abscopal Effect, Eliminating Distant Tumors In Preclinical Melanoma Study

Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company" or "Sona") is pleased to announce that a detailed biomarker analysis of the recently reported pre-clinical melanoma study conducted at Dalhousie University (the "Study") indicates that, beyond shrinking tumors on its own, Sona's Targeted Hyperthermia Therapy ("THT") also stimulates the innate immune system to target and eliminate untreated (contralateral) tumors when combined with a standard immunotherapeutic drug, IL-2. (See figure #1, below.) On the basis of efficacy data achieved in two different murine cancer models (triple negative breast cancer and malignant melanoma), the Company is now proceeding with safety and biocompatibility testing that will be required by regulating agencies to enter into human studies.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
E-Power Resources Inc. Announces Commencement of the 2024 Tetepisca Exploration Program

E-Power Resources Inc. Announces Commencement of the 2024 Tetepisca Exploration Program

Commencement of the Tetepisca Exploration Program for 2024

E-Power Resources Inc. (CSE: EPR) ("E-Power" or the "Company") announces that it has mobilized its exploration crew to the Tetepisca Graphite Project and the 2024 exploration program is underway.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
XReality Group

XReality Group Investor Kit

  • Corporate info
  • Insights
  • Growth strategies
  • Upcoming projects

GET YOUR FREE INVESTOR KIT

Latest Press Releases

Related News

×